source
- Summit and Akeso's ivonescimab beats Merck's Keytruda in Chinese NSCLC trialSummit Therapeutics and Akeso reported that their bispecific PD-1/VEGF antibody ivonescimab outperformed Merck's Keytruda in a Phase 3 HARMONi-2 trial conducted in China. The study enrolled first‑l…
- FDA approves Ionis’ Zanvastro as first disease-modifying therapy for Alexander diseaseThe U.S. Food and Drug Administration has granted approval to Ionis Pharmaceuticals' antisense oligonucleotide Zanvastro, the first therapy that modifies disease progression for Alexander disease.…